Variant · Other
BRAF Wildtype
CI-VAR-00004728Explore in graph →CIViC 426
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33090333
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| BRAF Wildtype | Cetuximab | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11664In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC) PMID 33090333 · Fisher et al., 2020 · Open in CIViC | civic |
| Malignant Breast Neoplasm1 | ||||||||
| BRAF Wildtype | Cetuximab | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11657In a clinical study of 49 patients, 10 patients with Breast Cancer (BC) and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. PFS of 6.7 weeks (95% CI… (full text at CIViC) | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available